

AFROCAB / LA CAB

Why some studies finish early?
Expert planning is often wrong.

ZOOM

28 February 2025


Simon Collins,
i-Base.info



Background examples

Unethical studies that caused harm?

- ***Any study*** with less than standard of care.
- Bad enrolment criteria: if your CD4 is very low and you need active ART.
- Bad ethics: study of two different fillers for facial lipoatrophy, giving one filler into each cheek.
- Bad science: transplanting fat from a buffalo hump into sunken cheeks.
- Already knowing outcome: AMP bNAbs studies?



Main study question

- Every research study has to start with a question (or hypothesis) – ie:
 - Do bNAbs work as PrEP?
 - Is it better to start ART early?
- This involves how to prove this idea. ie what measured results would prove this. What is the comparison or control group.
- This definition is called the **primary endpoint**.



Powering the study?

- The next step is to define every detail of the study.
- This is called **powering the study** so the results cant be by chance ($p < 0.05$)
- How to define the final result?
 - How many people will be needed?
 - How long will the study need to last?
 - How different to the results in each arm need to be?
- Experts use current knowledge to predict likely results – **but experts can get this wrong.**



1. Can bNAbs work as PrEP?

VRC01 AMP studies

bNAbs for prevention in Southern Africa: experts knew this wouldn't work before it even started.

<https://i-base.info/htb/39977>

Two large randomised studies: bNAb infusion every two months.

CONs: bNAb monotherapy. Old bNAb. No baseline sensitivity testing. No oral PrEP. Based on sub-type B. Didn't work overall.

??? - Ethics for participants who expected it might work.

PROs: High retention and adherence, worked in subset of people who were sensitive, **proof of concept**.




Corey L et al. NEJM, 2021.

2. Bangkok tenofovir study

Still the only oral PrEP study for people who inject drugs, 2005 – 2012.

<https://i-base.info/htb/22005>

- Delayed by activists for several years because the it didn't include access to ART for people who became HIV+
- No difference vs placebo for first three years – participants at very low risk.
- 2400 HIV– adults followed for 5 years.
- 17 vs 33 became HIV positive.



Choopanya K et al. Lancet 2013

3. Is is better to start ART early?

START study: When to start ART?

Large international **randomised** study (n=4600, in 35 countries): early (CD4 >500) vs late (CD4 = 350).

Worry about side effects and drug resistance?

Study closed early after DSMB review.

Even at high CD4 ART is better. Everyone offered immediate ART.

WHO guidelines changed within a month.



DSMB = Data and Safety Monitoring Board

Lundgren J et al. NEJM, 2015.

4. Does ART prevent transmission?

HPTN-052 study

Large intl randomised study - 1700 couples.

Q: Will early vs late ART (CD4 >350 vs 250) reduce HIV transmissions?

Experts thought that ART would only reduce transmission by about 30-50% (*definitely not U=U*).

DSMB closed study after 2 years (expected 5-6 years).

N=27 vs 1 new transmissions – ART reduced by 96%.

DSMB = Data and Safety Monitoring Board

Cohen M et al. NEJM, 2011.



5. Does TDF/FTC work as oral PrEP?

UK PROUD study in 545 gay and bisexual men.
Immediate PrEP vs deferred for 12 months.

Not powered to show efficacy.

BUT stopped early **after DSMB review**:

PrEP was 86% better than placebo.

3 vs 19 people became HIV+ nearly while waiting for PrEP.

Experts thought HIV rate was **3%** when it was really **9%**.

People were at a much higher risk = earlier answer.



DSMB = Data and Safety Monitoring Board

McCormack S et al. Lancet, 2015.

6. Is it ok to take a treatment break?

SMART study

Another large randomised study.

N=4500 people: continuous ART vs breaks in treatment (to reduce side effects of early HIV meds).

Closed by DSMB after 2 years – vs 7 years planned.

Experts were wrong. SMART showed untreated HIV caused what were thought to be side effects.

ART was much safer than people realised.

DSMB = Data and Safety Monitoring Board

El-Sadr W et al. NEJM, 2006.

Summary

- Good research studies are always better than expert opinion when people think they already know the answer.
- Keep an open mind that experts can make mistakes when planning studies.
- Independent DSMBs can stop studies early after the question is answered – limits further harm.

Thanks

simon.collins@i-base.org.uk